when does tirzepatide go generic May 13, 2036 - Whenwillgenericsemaglutide be available December 5, 2031 When Does Tirzepatide Go Generic? Understanding Patent Expirations and Future Availability

Whenwillgeneric tirzepatidebe available The question of when does tirzepatide go generic is a significant one for many individuals seeking more affordable access to this groundbreaking medication. Currently, there is no Mounjaro generic available in the United States, and the same applies to its brand-name counterpart, Zepbound. This means that for the foreseeable future, patients will rely on the innovator products, tirzepatide, sold as Mounjaro for type 2 diabetes and Zepbound for weight management.

The availability of a generic version of a drug hinges on the expiration of its patents and exclusivity periods. For tirzepatide, the primary molecule patent is anticipated to expire in 2036. However, this is not a straightforward date. Eli Lilly, the developer of tirzepatide, has secured several "follow-on" patents, which can further extend market exclusivity.FDA clarifies policies for compounders as national GLP-1 ... A more precise, though still subject to change, estimate for generic entry appears to be January 5, 2036.Compound versions of some weight loss drugs to be restricted Another widely cited date for the expiration of the tirzepatide patent is May 13, 2036.Tirzepatide

Furthermore, the U.S. Food and Drug Administration (FDA) grants "new chemical entity exclusivity," which for tirzepatide, is in place until at least May 2027.The molecule patent forTirzepatide willexpire in 2036, allowinggenericmanufacturers to produce their versions. However, the launch ofgenericformulations ... This exclusivity period prevents the FDA from approving generic Abbreviated New Drug Applications (ANDAs) until it has passed.

It's important to distinguish between a generic drug and a compounded version. Recently, regulatory changes have impacted compounded tirzepatide.The molecule patent forTirzepatide willexpire in 2036, allowinggenericmanufacturers to produce their versions. However, the launch ofgenericformulations ... As of March 2025, compounding pharmacies are largely prohibited from making their own versions of tirzepatide. This means compounded tirzepatide is not the same as a generic version and its availability has been restricted. While the FDA declared the tirzepatide shortage resolved in October 2024, this has not opened the door for generic productionSemaglutide & Tirzepatide Patent Considerations - DiversifyRx. Indeed, even with high demand, there are no generic versions available for these GLP-1 medications.

When a generic version of tirzepatide eventually becomes available, it is expected to lead to a significant decrease in price, making the treatment more accessible. This is a common pattern observed with other medications, such as semaglutide (the active ingredient in Ozempic and Wegovy). While semaglutide patents are set to expire in various countries starting in 2026, its molecule patent in the U.S. is expected to last until December 5, 2031.2025年4月15日—There's no generic for Mounjaro, and its active ingredient, tirzepatide, is prohibited from being sold in compounded form as of March 2025. For comparison, a generic version of the daily injectable GLP-1 medicine liraglutide was approved by the FDA in December 2024The first wave of genericised weight loss treatmentswillprovide greater choice and better availability for physicians, in managing patients' weight loss ....

For those seeking to understand these timelines, it is crucial to get details on FDA approval status, generic manufacturers, and patent expirations. While direct access to a generic form of tirzepatide is not an option currently, ongoing research and patent analyses are vital for monitoring future developments. The landscape of diabetes and weight management medications is dynamic, and understanding the patent expiration timelines will be key to predicting when tirzepatide will become more affordable. The FDA has also recently approved Zepbound for the treatment of moderate to severe obstructive sleep apnea, further expanding the therapeutic utility of tirzepatide.